Tesaro's Cancer Drug Meets Primary Endpoint in Late-Stage Trial
June 29 2016 - 8:00AM
Dow Jones News
Tesaro Inc. said Wednesday its ovarian cancer treatment drug
achieved its primary endpoint of progression-free survival in a
Phase 3 trial.
The company's shares soared 69% to $62.97 in premarket trading.
The company's shares had declined 29% so far this year through
Tuesday's close at $37.21.
The oncology-focused biopharmaceutical company said the results
from the trial showed that its drug, Niraparib, "significantly"
improved progression-free survival in women with recurrent ovarian
cancer, compared with a control group.
The trial included more than 500 patients with recurrent ovarian
cancer.
Niraparib is an oral, once daily treatment also in late-stage
clinical trials for use in breast cancer. And in April, Johnson
& Johnson announced it would invest $50 million in Tesaro, with
plans to develop and commercialize Tesaro's niraparib for treatment
of prostate cancer.
The company said it would release the full data from the Phase 3
study at the European Society for Medical Oncology congress in
October.
Write to Joshua Jamerson at joshua.jamerson@wsj.com
(END) Dow Jones Newswires
June 29, 2016 07:45 ET (11:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
